The World Congress on Targeting Metabesity 2017 is dedicated to major diseases and conditions to shared metabolic roots, including diabetes, obesity, and cardiovascular diseases.
Topics
- Cancer
- Validated targets
- Metabolic pathways and signaling
- Utility of animal models
- Animal study results
- Genomic and other means of high risk identification
- Evaluation of current and novel candidate interventions (nutritional, pharmacologic, life style)
- Epidemiology analysis and studies
- Clinical studies
- Meta-analyses of clinical studies and lessons learned from chemoprevention trials
- Aging and Sarcopenia
- Genomic and other means of high risk identification
- Metabolic pathways and signaling
- Animal model studies
- Validation of targets
- Methods to interpret translatability of animal results
- Evaluation of candidate interventions (nutritional, pharmacologic, life style)
- Proposed clinical design approaches
- Clinical efficacy endpoints validation (functional and person-reported instruments)
- Epidemiology analysis and studies
- New clinical study results
- Specific bioethical considerations
- Comparison of major regulatory positions
- Neurodegeneration
- Validation of targets
- Metabolic pathway and signaling
- Methods to enhance translation of animal results
- Animal model studies
- Proposed clinical design approaches
- Clinical efficacy endpoints validation
- Comparison of major regulatory positions
- Clinical studies
- Diabetes
- Islet biology (embryogenesis and homeostasis of islet mass and function)
- Metabolic pathway and signaling
- Validation of metabolic, inflammatory, and immunologic targets
- Immunity (pathogenesis and interventions)
- Methods to enhance translation of animal results
- Animal model studies
- Clinical efficacy endpoints validation
- Genomic and other means of high risk identification
- Clinical studies
- Proposed clinical design approaches
- Lessons learned from T1D and T2D prevention trials
- New analyses of reported clinical trials
- Comparison of major regulatory positions
- Metabesity-general approaches and tools
- Animal model development
- Metabesity pathways and signaling (choke points and pleotropic agents that leverage 2 or more major clinical outcomes)
- Efficacy endpoints-functional, quality life survival, person-reported
- Biomarkers and imaging
- General issues related to repurposing approved therapies
- Microbiome (mechanisms, characterization, interventions)
- Biostatistical methods
- Acquiring and managing big data
- Regulatory approaches
- Cost-effectiveness approaches relevant to payors and policy makers
- Education
- "Apps" and other engagement and tracking tools
- Bioethics
- Econometrics
- Public policy and public health approaches
Who should Attend
- R&D personnel
- Medical Professionals
- Regulatory Affairs specialists
- CEOs
- CRAs
- CROs
- Research facility managers
- QA personnel
- Start-up Companies
- Pharmaceutical Company representatives
